Dana-Farber Cancer Institute

"In this case study, we report the challenges and lessons learned in the evaluation and deployment of LLMs at the Dana-Farber Cancer Institute for use in all business areas, including basic research, clinical research, and operations, but not in direct clinical care. 

"In early discussions about whether and how to proceed, we realized that although some risks could be mitigated by clear policy guardrails and a secure technical environment, others would remain, including those regarding compliance with rapidly evolving regulations. 

"We also recognized that substantial, ongoing work would be required to ensure appropriate ethical consideration of each use case and to ensure patient- and human-centric decision-making. 

"After engaging in discussions over many months and employing a process framework for ethical implementation of AI in our cancer center, we believed it would be better to tackle these challenges as a community, rather than prohibit the use of LLMs altogether. 

"Here, we detail aspects of sponsorship, governance, technical implementation, program launch, socialization, user feedback, and ongoing support and user training in preparation to make generative AI LLMs broadly available to our 12,500-member workforce in a compliant, auditable, and secure manner."

Comments

Popular posts from this blog

Perplexity

Aphorisms: AI

DeepAI's Austen on China